Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHealthPartners Prior Auth & Step Therapy Coverage …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentHealthPartnersPolicy N/A

    Commercial Formulary Prior Authorization and Step Therapy Coverage Criteria — Pharmacy & Specialty Drugs

    Customize your policy alerts

    Sign up for all HealthPartners policy alerts

    Know when HealthPartners releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists HealthPartners' commercial drug-list prior authorization (PA) and step therapy (ST) criteria for pharmacy and specialty drugs, explaining when PA/ST is required and linking to specific drug criteria. It affects providers and members covered under HealthPartners commercial pharmacy benefits.

    Policy Summary
    PayerHealthPartners
    PolicyFormulary prior authorization and step therapy coverage criteria (pharmacy & specialty drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document required trials/attestations (e.g., step therapy failures, allergy to generic, lab values or specialist documentation) per the product-specific criteria or linked PA document.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    >100drugs with PA criteria listed on pages shown
    NCapplicable state
    common reasonscommon reasons for PA
    multipleexternal PA PDFs/webpages
    1withdrawn product noted

    Coverage Criteria and Product-Level Rules

    General PA criteria patterns

    Coverage for listed drugs is conditional per drug-specific criteria

    General PA conditions: Drug is reserved per FDA indication OR for patients with documented allergic reaction to equivalent generic OR for patients with inadequate response to preferred alternatives or with medical contraindications to their use.

    Many drug entries follow one of these recurring criteria patterns.

    Drug-specific example: Abilify MyCite

    Certain specialty products reference unique multi-point criteria

    Abilify MyCite specific criteria: All three must be met: 1) reserved per FDA indications; AND 2) patient has documented compliance concerns with oral therapy; AND 3) injectable therapy is contraindicated or oral therapy cannot be used.

    Extracted verbatim from listing.

    Policy Summary
    PayerHealthPartners
    PolicyFormulary prior authorization and step therapy coverage criteria (pharmacy & specialty drugs)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionObtain prior authorization and document required trials/attestations (e.g., step therapy failures, allergy to generic, lab values or specialist documentation) per the product-specific criteria or linked PA document.
    SourceLink
    On This Page
    Coverage Criteria and Product-Level RulesProvider Requirements, Prior Authorization & Denial RisksDefinitions and Key TermsInitial Therapy Requirements and DurationsContinuation and Renewal CriteriaStep Therapy Rules and Required TrialsKey Clinical Thresholds and Quantity/Code NotesProduct Quantity Limits and Dispensing RulesSite-of-Care and Specialty Management RequirementsBackground and Policy Scope

    Common PA criteria patterns (documented across multiple product entries in these chunks)

    Entries in these chunks follow one of several common PA logic patterns:

    Allergy-to-generic pathway: Prior authorization reserved for patients with a documented allergic reaction to the equivalent generic.

    Many single-tablet/genericable products use this pathway.

    Failure-of-preferred-products pathway: Prior authorization reserved for patients with an inadequate response to two preferred alternatives or for patients with medical contraindications to their use; documentation in the medical literature of clinical benefit over preferred alternatives may be required.inadequate response to 1–2 preferred alternatives (varies)

    Some products specify one preferred alternative rather than two.

    FDA-indication and guideline-aligned pathway: Reserved for FDA-approved indications and may require alignment with clinical trial criteria or specialty guidelines; approvals may be time-limited.

    Used for specialized agents and those with external PA documents.

    Provider specialty or patient-characteristic requirement: Certain products require prescribing by specific specialists or patient characteristics (e.g., AUVI-Q 0.1 mg requires allergist prescriber and weight 7.5–10 kg).

    Explicit examples appear in the listing.

    General PA coverage logic (segment)

    Coverage reserved under one of these common conditions depending on product:

    Allowed when specific condition met: (A) Documented allergic reaction to equivalent or preferred generic/brand; OR (B) Inadequate response to specified number of preferred alternatives (commonly two) or failure of preferred product/dosage form; OR (C) FDA‑approved indication with provider attestation or specialist prescribing as indicated.see individual drug entry

    This segment lists drugs with one of these reservation logics applied.

    Specialty drug criteria

    Certain specialty agents have additional requirements

    CAYSTON-specific: Patient must have cystic fibrosis with Pseudomonas aeruginosa; AND prescription/management by a cystic fibrosis treatment center specialist; AND quantity limited to one 28-day package per month; initial approval 12 months; renewals annually with documentation of specialist visit and treatment effectiveness.one 28-day package/month

    From CAYSTON entry.

    General prior authorization conditions

    Common conditional coverage language in this excerpt

    General reserve conditions: Coverage is reserved for: (1) FDA‑approved indications; OR (2) patients with an inadequate response to two preferred alternatives; OR (3) patients with medical contraindications to preferred alternatives; OR (4) documented allergic reaction to the equivalent generic formulation; some products add specialist prescriber or documentation requirements.varies by product

    Applies broadly across multiple listed products in the excerpt

    Not medically necessary — deflazacort

    Specific not medically necessary determination

    Deflazacort NMN: Deflazacort (including branded formulations) is considered not medically necessary because evidence is insufficient to establish superiority to much less costly alternatives; brand formulations may be reserved only for patients with a documented allergic reaction to the equivalent generic.

    Explicit NMN statement present for multiple deflazacort entries.

    Dalfampridine (DALFAMPRIDINE ER) criteria

    Dalfampridine approval logic

    Dalfampridine approval: Member must have multiple sclerosis AND be currently able to walk 25 feet AND physician attestation that patient has difficulty walking AND prescribing by a neurologist AND dosing not to exceed 10 mg twice daily. Initial approval: six months; continuation requires documented improvement in ambulation for ongoing authorization.initial 6 months then annual if improved

    Contains time‑limited initial approval and renewal conditions.

    Cystinosis ophthalmic product criteria

    Cystinosis ophthalmic products

    CYSTADROPS / CYSTARAN: Reserved for prescribing by a specialist AND diagnosis of cystinosis. Initial approvals: three months. Renewals require documentation of clinical treatment effect (slit lamp exam notes) and may be approved for up to one year.initial 3 months; renewals up to 1 year

    Monitoring requirement specified for renewals.

    Opioid attestation requirement

    Opioid-specific attestation

    Long-acting opioid attestation: Long-acting opioids require provider attestation that therapy is managed per standard opioid prescribing guidelines AND evidence of an inadequate response to a recent adequate trial (minimum 30 days continuous use) of a short-acting opioid.minimum 30 days short-acting opioid trial

    Specified for long-acting opioid products across the list.

    Common prior authorization criteria (partial)

    General prior authorization conditions appearing across listed products (partial list):

    General PA conditions: Coverage reserved for patients with: (A) inadequate response to two preferred products; OR (B) medical contraindication to preferred alternatives; OR (C) documented allergic reaction to equivalent generic; OR (D) prior inadequate response to specified preferred dosage forms.varies by product

    Many entries repeat these patterns; some drugs reference external PA PDFs for full criteria.

    Drug-specific exceptions: Certain products are reserved only for FDA‑approved indications; others require documented failure of a specific number/type of alternatives (examples include EMSAM and others).

    See linked product PDFs for full logic where provided.

    Allergy or brand-equivalent reservation

    Many products are covered only under specific reservation rules, for example:

    Allergy-reserved products: Coverage reserved for patients with a documented allergic reaction to the equivalent generic or brand.

    Examples appear throughout the formulary listings.

    Failure of preferred alternatives

    Other products require prior trials or contraindications to preferred alternatives:

    Two-preferred-alternatives failure: Coverage reserved for FDA‑approved indications for patients with an inadequate response to two preferred alternatives OR for patients with medical contraindications to their use; documentation in the medical literature may be required to demonstrate benefit.inadequate response to 2 preferred alternatives

    Examples include many topical, systemic, and specialty agents.

    Gattex coverage criteria

    Specialty agent (example) with condition-specific criteria:

    Gattex (teduglutide) criteria: Reserved for adult patients with short bowel syndrome significantly impaired due to chronic parenteral nutrition dependence (>=1 year and >=3 days/week). Initial approvals: three months; reauthorizations up to one year with documented reduction in parenteral nutrition volume.>= 1 year and >= 3 days/week

    Condition- and documentation-specific criteria.

    Long-acting opioid PA criteria

    Opioid-specific coverage requirement:

    Long-acting fentanyl and opioid products: Reserved for patients with an inadequate response to preferred alternatives or with medical contraindications; AND provider attestation that opioid therapy is managed per standard guidelines, including an adequate recent short-acting opioid trial (minimum 30 days continuous).30 days trial

    Applies to multiple long-acting opioid formulations listed.

    General PA coverage criteria (H–I products)

    Covered when the product-specific prior authorization reservation is met

    Primary reservation conditions: Coverage is available when ALL applicable reservation conditions for the listed product are met (examples: documented allergy to generic; inadequate response to one or two preferred products; medical contraindication to preferred therapies; FDA‑approved indication when specified).

    Many entries reference external PA documents for full criteria and required documentation.

    General coverage stance for listed drugs (I-L)

    Coverage and PA stance for listed products (I-L) — conditions under which PA is granted or products are reserved

    Product-specific PA links: Multiple products include direct links to detailed prior authorization criteria documents hosted on HealthPartners' site; providers must follow linked criteria for approval.

    See linked product page for full criteria and required documentation.

    Reserved for inadequate response/contraindication: Many products are reserved for patients with an inadequate response to preferred alternatives or with medical contraindications; number of required trials varies by product (commonly one or two).trial of 1–2 preferred alternatives

    Examples vary across listings.

    Reserved for documented allergic reaction to generic: Several brand products are reserved only for patients with a documented allergic reaction to the equivalent generic.documented allergic reaction

    Examples include multiple brand/generic pairs.

    FDA‑approved indication requirement: Some products are limited to FDA‑approved indications and require PA when used for those indications with inadequate response to preferred alternatives.FDA‑approved indication

    Examples reference specialty and oncology agents.

    Standard coverage criteria (grouped)

    Covered when ALL of the following are met (applies per-product as specified):

    Preferred-alternative trial: Documentation of inadequate response to the required number of preferred alternatives (commonly 1–2; some products require 3) OR documented medical contraindication to preferred alternatives.varies by product

    Many entries specify 'inadequate response to two preferred alternatives' or similar.

    FDA-approved indication or linked criteria: Use is for an FDA-approved indication OR meets product-specific linked prior authorization criteria when a link is provided.N/A

    Several products point to external PDFs or coverage pages.

    Opioid-specific requirement: For long-acting opioids, provider attestation that therapy is managed per standard opioid prescribing guidelines AND that the patient had an adequate recent trial (minimum 30 days continuous) with a short-acting opioid.minimum 30 days

    Applies to named long-acting opioids.

    Allergy-based coverage

    Covered when ALL of the following are met:

    Documented allergy to generic or preferred: Coverage reserved for patients with a documented allergic reaction to the equivalent generic or preferred product.N/A

    Frequently used for brand products where generic equivalent exists.

    General reservation and step/failure criteria

    Covered when the specific reservation condition for each product is met

    All applicable conditions: When the product-specific reservation applies (examples: documented allergic reaction to equivalent generic; inadequate response to two preferred alternatives; FDA‑approved indication with prior failures), AND any product-specific documentation (lab values, culture results, provider attestation) is provided.

    Individual product entries specify exact requirements; see linked product-specific criteria where provided.

    Nexletol/Nexlizet specific coverage conditions

    Nexletol/Nexlizet specific coverage conditions

    Nexletol/Nexlizet: 1) FDA‑approved indication; AND 2) LDL cholesterol >= 70 mg/dL despite high‑intensity statin therapy or with contraindication to statin; AND 3) inadequate response to ezetimibe OR documented allergy/contraindication to ezetimibe. Approvals: one year; reauthorization contingent on LDL reduction per provider attestation.LDL >= 70 mg/dL

    Reauthorization requires documentation of LDL reduction.

    Long-acting opioid criteria

    Long-acting opioids (multiple named products) coverage conditions

    Long-acting opioid products: 1) Member has tried and failed two preferred products OR has medical contraindications; AND 2) Provider attestation that opioid therapy is managed per standard opioid prescribing guidelines AND that the patient had an inadequate response to a recent adequate trial (minimum 30 days continuous) of a short-acting opioid.30 days

    Applies to multiple long-acting opioids (e.g., morphine ER, hydromorphone ER, fentanyl patches).

    Nuzyra specific coverage conditions

    Nuzyra specific coverage conditions

    Nuzyra (antibiotic): 1) FDA‑approved indication; AND 2) prescribing by or in consultation with Infectious Disease providers as indicated; AND 3) inadequate response to standard treatments or medical contraindication to them (standard treatments include quinolones for CAP and linezolid for ABSSSI); AND 4) culture and sensitivity results required.

    See product-specific PDF for details.

    Common coverage rules in excerpt

    Common coverage rules appearing in this excerpt

    Reservation for documented allergic reaction to generic: Multiple products are reserved for patients with a documented allergic reaction to the equivalent generic.

    Examples appear across the formulary.

    Reserved for FDA-approved indications or after failure of preferred alternatives: Many products are reserved for FDA‑approved indications and/or require inadequate response to two preferred alternatives or medical contraindications to their use.trial of 2 preferred alternatives (common)

    Examples: numerous topical, systemic, and specialty agents.

    Specific multi-step requirement example: Some products require failure of three preferred therapies (example: omeprazole‑sodium bicarbonate for esophagitis requires trial/failure of omeprazole, pantoprazole, and lansoprazole).3 failed preferred therapies

    Product‑specific examples exist in the listing.

    PEGASYS regimen and documentation: PEGASYS prior authorization requires specialty prescriber and documentation including HCV genotype and viral load and intolerance/adverse effects to prior Peg‑Intron where applicable; regimens must meet HealthPartners criteria and durations vary by genotype.HCV: genotype and viral load

    See PEGASYS entry for specifics.

    General coverage criteria patterns

    Standard reservation/authorization rules observed in these entries:

    Failure/Contraindication requirement: Product is reserved for FDA‑approved indications and requires inadequate response to two preferred alternatives OR medical contraindication to preferred alternatives.two preferred alternatives

    Applies to multiple listed products.

    Allergy to generic: Product reserved when patient has documented allergic reaction to equivalent or preferred generic.documented allergy

    Applies to many brand/generic pairs in list.

    Specialty product admin/renewal: Certain specialty agents (e.g., Pulmozyme) require specialist management, time‑limited initial approval (12 months) and renewal documentation of specialist visit and effectiveness.12 months

    See Pulmozyme entry.

    Market withdrawal: Products withdrawn from market (e.g., Relyvrio) are not eligible for coverage.N/A

    Relyvrio withdrawn 4/4/2024.

    General coverage reservation rules

    General reservation and PA patterns observed in this extract (applies per listed product as noted):

    All listed reservation types: Coverage reserved when ONE of the following product‑specific conditions is met: documented allergic reaction to the equivalent generic; inadequate response to one or two preferred alternatives; medical contraindication to preferred alternatives; FDA‑approved indication only; prescribing by/consultation with a specialist per label; documentation of medical necessity (e.g., literature evidence); or monitoring/attestation per opioid prescribing guidelines for specific opioids.

    Specific products enumerate which of these apply; see individual product line.

    General reserved-use and external-PA rules

    Products covered only under specified reserved conditions or per linked PA criteria

    Reserved for documented allergic reaction to equivalent generic: Multiple topical or oral products are reserved for patients with a documented allergic reaction to the equivalent generic.

    See individual product line for exact wording.

    Reserved for inadequate response to preferred alternatives: Several agents are reserved for patients with an inadequate response to one or more preferred alternatives or two preferred alternatives (varies by product).

    Examples include topical and systemic agents.

    Subject to detailed external PA criteria: Many specialty and oncology agents require review per external HealthPartners PA documents linked in the listing; providers must submit information as required by those documents.

    Provider must follow linked PA document for clinical criteria and required documentation.

    Somatuline/Somavert specific: Somatuline Depot and Somavert: patient not a candidate for curative surgery AND failure of one somatostatin analogue; initial approval 6 months; annual approval for responders with demonstrated effect.6 months initial

    Specialty agent renewal logic.

    Age/diagnosis-specific coverage

    Products with gender/age/diagnostic-specific requirements

    Testosterone products: Certain testosterone formulations require either (1) diagnosis of gender dysphoria OR (2) FDA‑approved indication with documented testosterone deficiency < 300 ng/dL; some formulations additionally require inadequate response or contraindication to two or more preferred alternatives.<300 ng/dL

    Applies to several testosterone products listed.

    Tascenso ODT 0.25 mg: Requires ALL of: age >=10 years; AND weight <=40 kg; AND inability to take oral Gilenya capsules.age >=10 && weight <=40 kg

    Product‑specific eligibility example.

    Testosterone product criteria

    Covered when ALL of the following (product-specific) requirements are met:

    Testosterone products: Either (1) diagnosis of gender dysphoria OR (2) FDA‑approved indication with documented testosterone deficiency <300 ng/dL; AND where specified, inadequate response or contraindications to two or more preferred alternatives are documented.<300 ng/dL

    Applies to multiple testosterone formulations (gels, injections, pumps).

    Tobramycin inhalation criteria

    Covered when ALL of the following are met for Tobramycin ampules/PAK:

    Tobramycin CF inhalation: (1) Patient has cystic fibrosis with known Pseudomonas aeruginosa in the lungs; AND (2) prescribed and managed by specialists from a cystic fibrosis treatment center; AND (3) quantity up to one 56‑count carton per 56 days (or one 28‑day package per month for packaged formulations). Initial approvals: 12 months; renewals annually with documentation of CF center visit and treatment effectiveness.one 56‑count carton per 56 days (or one 28‑day package/month)

    Site‑of‑care and quantity limits apply.

    Tramadol ER criteria

    Covered when ALL of the following (Tramadol ER / IR related) are met:

    Tramadol ER: Provider attestation that therapy is managed per standard opioid prescribing guidelines AND prior adequate trial of tramadol immediate release (minimum 30 days continuous use). Age limits: reserved for adults and children >= 12 years. IR opioid new‑user supply limits apply (7‑day first fill; 14‑day per episode) unless prior authorization granted.30 days

    Attestation and age/quantity edits are required.

    General reserved-use conditions

    Covered when ANY of the following general reserved-use conditions apply (examples across multiple products):

    Allergy to preferred generic: Product reserved for patients with a documented allergic reaction to the equivalent preferred generic.documented allergic reaction

    Appears repeatedly for many brand products.

    Inadequate response/contraindication to preferred: Product reserved for patients with an inadequate response to a preferred dosage form or two preferred alternatives, or with medical contraindications to their use; documentation in the medical literature may be required to show benefit over preferred alternatives.failure to preferred agents

    Documentation requirements vary by product.

    Agamree is designated not medically necessary because the clinical evidence does not demonstrate superiority to less costly alternatives.

    Certain topical ophthalmic antibiotics such as BESIFLOXACIN and BESIVANCE are reserved for treatment of MRSA infection, implying these agents are not authorized for other indications unless the MRSA-specific criteria are met.

    Some products are limited to prescribing by specific specialists or within defined clinical programs; for example, CAYSTON must be prescribed and managed by clinicians at a cystic fibrosis treatment center as part of the coverage reservation.

    Deflazacort is treated as not medically necessary because available evidence does not establish superiority to much less costly alternatives; brand formulations are only reserved when there is a documented allergic reaction to the equivalent generic.

    The policy distinguishes brand and generic deflazacort: brand names (e.g., JAYTHARI, KYMBEE) are reserved only for patients with a documented allergic reaction to the equivalent generic; otherwise deflazacort is considered not medically necessary.

    Several products are explicitly limited to FDA‑approved indications only; use outside FDA‑approved indications requires separate criteria or will not be covered under the reservation language.

    Coverage for some devices or products is restricted to patients using compatible device ecosystems; for example, certain glucose sensors/transmitters are reserved for patients using a Medtronic insulin delivery device due to integrated functionality.

    Brand deflazacort products (listed examples include JAYTHARI and KYMBEE) are considered not medically necessary absent documentation of allergy to the generic; brand coverage is limited to documented allergic reactions to the generic equivalent.

    There are no blanket universal exclusions in this excerpt; instead, individual product entries may restrict coverage to FDA‑approved indications or other product‑specific reservation conditions.

    For OCALIVA, HealthPartners notes that health care professionals should stop prescribing Ocaliva and refers clinicians to the Primary Biliary Cholangitis policy for additional direction.

    For OXBRYTA the guidance states health care professionals should stop prescribing the product and that patients/caregivers should consult their clinician about stopping and selecting alternative therapy.

    Requests for RELYVRIO will be denied because the product has been withdrawn from the market and is not eligible for coverage as of 4/4/2024.

    Several listed products are reserved for FDA‑approved indications or require specialist prescribing; when a product is so reserved, other uses not meeting those requirements will not be approved.

    Combination products (for example, SUMATRIPTAN‑NAPROXEN) are reserved for patients who have tried and failed the individual active ingredients given separately; coverage requires documentation of prior failure or allergy as specified.

    Many formulary entries reference external prior authorization PDFs or HealthPartners coverage pages; providers must follow those linked PA documents for the detailed criteria and submission instructions.

    Agamree is specifically listed as not medically necessary because there is insufficient evidence to establish superiority to less costly alternatives.

    Deflazacort is reiterated as not medically necessary in multiple entries (including PYQUVI/PYQUVI‑related listings); brand formulations remain reserved only when a documented allergic reaction to the generic exists.

    Deflazacort is repeatedly characterized as not medically necessary absent evidence of superiority; brand versions may be reserved solely for documented allergy to the generic equivalent.

    Policy language for deflazacort appears in multiple product lines: the generic and brand formulations are considered not medically necessary except where brand use is justified by a documented allergic reaction to the generic.

    Brand deflazacort coverage is limited: brand products are reserved only for members with a documented allergic reaction to the equivalent generic formulation; otherwise deflazacort is not eligible for coverage as not medically necessary.

    For long‑acting opioid formulations, the policy requires a provider attestation that therapy is being managed per standard opioid prescribing guidelines and that the patient had an adequate recent trial (minimum of 30 days continuous use) of a short‑acting opioid prior to authorization.

    PYQUVI (deflazacort listing) is noted as not medically necessary because evidence does not demonstrate superiority to less costly alternatives; brand coverage may be allowed only for documented allergy to generic equivalents.

    Provider Requirements, Prior Authorization & Denial Risks

    Prior Authorization

    Prior authorization required for listed drugs

    Many medicines listed on the HealthPartners drug list require prior authorization. Specific approval criteria differ by product and (where provided) must be followed per the HealthPartners prior authorization documents linked for individual drugs.

    • Follow product-specific PA documents or linked HealthPartners URLs for full criteria.
    Prior Authorization

    General prior authorization requirement

    Coverage of numerous branded or non‑preferred products is limited to patients with a documented allergic reaction to the equivalent generic, or to patients who have had an inadequate response to preferred alternatives; prior authorization is required to confirm these conditions.

    • Provider must supply documentation of documented allergy to the generic or evidence of inadequate response to preferred agents when requested.
    Prior Authorization

    AUVI‑Q 0.1 mg specific PA requirements

    AUVI‑Q 0.1 mg autoinjector is reserved for patients who meet all three specific criteria: prescribing by an allergist, patient weight between 7.5 kg and 10 kg, and a history of anaphylaxis; prior authorization must document these items.

    • Prescriber specialty: allergist
    • Patient weight: 7.5 kg–10 kg
    • History of anaphylaxis documented in chart
    Prior Authorization

    Prior authorization general rule

    Many entries require prior authorization and either reference product‑specific PA documents or reserve coverage for patients with documented allergic reactions or inadequate responses to preferred alternatives; providers must follow the referenced PA instructions for those products.

    • If an external PA PDF/URL is listed, submit documentation per that product's linked criteria.
    Prior Authorization

    External PA documentation

    Several products point to external HealthPartners prior authorization documents (PDFs or webpages); providers must consult and submit documentation according to those external PA criteria.

    • Locate and follow the HealthPartners URL or PDF referenced in the formulary entry when filing the PA.
    Prior Authorization

    Prior authorization for non-preferred use

    Many drugs are reserved for FDA‑approved indications or for patients who have had an inadequate response to preferred alternatives; prior authorization is required when used for non‑preferred indications or after failure of preferred therapies.

    • Provide documentation of prior trials or contraindications to preferred alternatives as part of the PA.
    Prior Authorization

    External product-specific PA references

    Some product entries refer to separate, product‑specific prior authorization documents hosted as external PDFs/webpages; providers must follow those external product‑specific PA references when requesting authorization.

    • Submit supporting documentation exactly as required by the referenced product PA document.
    Denial Risk

    Deflazacort coverage stance

    Deflazacort (PYQUVI / brand formulations) is considered not medically necessary due to insufficient evidence of superiority; brand product coverage is reserved only for members with a documented allergic reaction to the equivalent generic.

    • If requesting brand deflazacort, include documentation of a documented allergic reaction to the generic equivalent.
    Prior Authorization

    Prior authorization required for listed drugs

    Prior authorization is required for many listed drugs and commonly requires documentation such as failure/inadequate response to two preferred products, medical contraindication to preferred alternatives, or specialist prescribing as specified per product.

    • Provide evidence of trials and failures of preferred therapies (often two) when indicated in the product entry.
    Prior Authorization

    Follow product-specific PA links

    When a product references a product‑specific PA webpage or PDF, providers must follow the full criteria and instructions on that linked page to obtain authorization.

    • Attach any forms or required documentation listed on the product‑specific PA link.
    Prior Authorization

    External PA document required

    Many products reference specific prior authorization criteria documents (URLs) that must be followed for approval; providers should consult the linked document and include required evidence when submitting the PA.

    • Submit documentation per the HealthPartners linked PA criteria for that product.
    Prior Authorization

    Allergic reaction reservation

    Several inhaled steroid or combination products are reserved for patients with a documented allergic reaction to the equivalent generic; prior authorization must include documentation of that allergic reaction.

    • Provide chart notes or allergy testing evidence showing allergic reaction to the generic equivalent.
    Prior Authorization

    PA required for listed products

    Prior authorization is required for listed products when they are reserved for patients with allergic reactions to preferred alternatives, medical contraindications, or after failure of preferred therapies; include documentation of those conditions in the PA request.

    • Document inadequate response to preferred agents or medical contraindications as applicable.
    Prior Authorization

    Follow product-specific PA documents

    Several products point to separate product‑specific PA documents provided via HealthPartners URLs (examples include HADLIMA, HAEGARDA, HARLIKU, HARVONI, HEMGENIX); providers must follow those external product PA documents when requesting authorization.

    • Include any product‑specific forms or evidence required by the linked HealthPartners document.
    Prior Authorization

    PA required for listed products

    Many listed products require prior authorization; individual drug entries specify product‑level criteria or external links which providers must follow when submitting requests.

    • Check each formulary entry for product‑specific PA instructions or external link.
    Prior Authorization

    PA reserved for inadequate response or contraindication

    Some products are reserved for FDA‑approved indications and require documentation that the member had an inadequate response to two preferred alternatives or has a medical contraindication to those alternatives; include that documentation in the PA.

    • When two preferred failures are required, submit records showing the trials and outcomes.
    Prior Authorization

    General prior authorization rule

    Many listed products require prior authorization when the patient has not tried and failed preferred alternatives or lacks a documented contraindication; long‑acting opioids additionally require provider attestation of opioid management and evidence of a prior adequate short‑acting opioid trial.

    • For long‑acting opioids, include provider attestation and documentation of a minimum 30‑day continuous short‑acting opioid trial.
    Prior Authorization

    Product-specific prior authorization (linked)

    Certain drugs include a linked product‑specific prior authorization criteria page or PDF that must be used; providers must follow those linked instructions and submit required documentation.

    • Attach evidence exactly as requested on the linked PA PDF or web page.
    Prior Authorization

    PA required for allergy- or step-restricted products

    Many listed products are reserved for patients with a documented allergic reaction to the equivalent generic or otherwise require prior authorization per the listed conditions or external PA links; providers must document the allergy or step failures when requesting coverage.

    • Provide allergy documentation or prior therapy failure documentation as specified in the product entry.
    Prior Authorization

    PA for long-acting opioids

    Long‑acting opioid formulations require prior authorization that includes a provider attestation the opioid therapy is managed per standard opioid prescribing guidelines and evidence of inadequate response to a recent adequate short‑acting opioid trial of at least 30 days continuous use.

    • Provider attestation that care follows opioid prescribing guidelines
    • Documentation of minimum 30 days continuous short‑acting opioid trial
    Prior Authorization

    PA with lab and prior therapy criteria (Nexletol/Nexlizet)

    Nexletol and Nexlizet require prior authorization for FDA‑approved indications plus documentation that LDL remains >= 70 mg/dL despite standard therapy (high‑intensity statin) and inadequate response to ezetimibe or contraindication to ezetimibe; approvals are for one year with reauthorization contingent on LDL reduction attestation.

    • Provide LDL result (>= 70 mg/dL) and prior therapy history (high‑intensity statin ± ezetimibe) in the PA.
    Prior Authorization

    Prior authorization required for listed products

    Many listed products require prior authorization per HealthPartners and may reference linked PDF criteria for specific products; follow those links and submit required documentation when requesting authorization.

    • If the formulary entry lists a linked PDF, use it to guide the PA submission.
    Documentation Required

    PEGASYS prior authorization

    PEGASYS prior authorization requires prescribing by gastroenterology, hepatology, or infectious disease specialists and, when used for HCV, must include HCV genotype and viral load and documentation of intolerance or adverse effects from prior Peg‑Intron; the regimen must meet HealthPartners coverage criteria.

    • Include prescriber specialty and HCV genotype/viral load when applicable
    • Document prior Peg‑Intron intolerance/adverse effects if claimed
    Prior Authorization

    PERPHENAZINE‑AMITRIPTYLINE prior authorization

    Perphenazine‑amitriptyline is reserved for FDA‑approved indications and requires prior authorization when the patient has had an inadequate response to two preferred alternatives or has medical contraindications to their use.

    • Provide documentation of two preferred therapy failures or contraindications.
    Prior Authorization

    PLAN B ONE‑STEP prior authorization

    Plan B One‑Step requires prior authorization when the patient has significant side effects from two or more preferred alternatives or when a provider states the product is medically necessary for contraception.

    • Document prior side effects to two or more preferred alternatives or include provider statement of medical necessity.
    Denial Risk

    PYQUVI coverage stance

    PYQUVI (deflazacort) is considered not medically necessary due to insufficient evidence of superiority; brand product coverage is reserved only for patients with a documented allergic reaction to the generic equivalent.

    • Requests lacking documentation of the required allergy will be handled as not meeting criteria.
    Prior Authorization

    Authorization durations and links

    Some products specify initial and re‑authorization durations (example: Reyvow initial authorization 6 months; re‑authorization 12 months); providers must request reauthorization and supply documentation per the product entry.

    • Plan reauthorization submissions to meet the specified timeline and include required evidence.
    Prior Authorization

    Linked PA criteria

    Certain products link to full prior authorization criteria pages or PDFs (e.g., Roctavian, Romidepsin, Romvimza); providers must follow those linked PA criteria and submit required documentation.

    • Attach documentation requested on the linked product PA page when submitting the PA.
    Prior Authorization

    Somatostatin analogues PA requirement

    Somatuline Depot and Somavert are reserved for patients for whom surgery is not an option or not curative and who have failed one somatostatin analogue; initial approvals are for six months with annual reauthorization for responders.

    • Document prior somatostatin analogue failure and that surgery is not an option or not curative.
    Prior Authorization

    Talicia PA requirement

    TALICIA is reserved for FDA‑approved indications and requires treatment failure to one first‑line option (treatment failure defined per product criteria such as positive fecal antigen or endoscopy); prior authorization must document that failure.

    • Provide objective evidence of first‑line treatment failure (e.g., fecal antigen or endoscopy) as defined.
    Prior Authorization

    Tascenso ODT eligibility

    Tascenso ODT 0.25 mg tablet is reserved for patients meeting all three criteria: age ≥10 years, weight ≤40 kg, and inability to take oral Gilenya capsules; prior authorization must document all three.

    • Include patient age, weight, and rationale for inability to take oral capsule in the PA submission.
    Prior Authorization

    Allergy to generic required for brand coverage

    Many branded products are reserved for patients with a documented allergic reaction to the equivalent generic; prior authorization must include documentation confirming the allergy to the generic.

    • Supply allergy documentation (chart note or test result) when requesting branded product coverage.
    Prior Authorization

    Testosterone products prior authorization

    Testosterone products require either a diagnosis of gender dysphoria OR an FDA‑approved indication with documented testosterone deficiency (< 300 ng/dL); some formulations also require inadequate response or contraindications to two or more preferred alternatives.

    • Provide testosterone level (<300 ng/dL) or diagnosis of gender dysphoria, and documentation of prior therapy failures when required.
    Prior Authorization

    Tobramycin CF-specific prior authorization

    Tobramycin inhalation products (300 mg ampules and PAK) are reserved for cystic fibrosis patients with Pseudomonas aeruginosa and must be prescribed and managed by specialists from a cystic fibrosis treatment center; quantity limits and renewal documentation (specialist visit within 12 months and evidence of effectiveness) are required.

    • Prescriber should be a CF center specialist and include documentation of Pseudomonas aeruginosa and recent CF center visit for renewals.
    Prior Authorization

    Tramadol IR/ER prior authorization and edits

    Tramadol ER requires prior authorization after a minimum 30 days continuous use of tramadol IR; it is reserved for adults and children 12 years and older and requires provider attestation that therapy is managed per standard opioid prescribing guidelines.

    • Document minimum 30‑day continuous IR trial, patient age, and provide provider attestation per opioid prescribing guidelines.
    Step Therapy

    Step therapy overview

    Step therapy requires providers to document prior trials and failures of one or more preferred medicines before coverage of a step therapy drug will be approved; exceptions include documented allergy or medical contraindication to preferred agents.

    • Include records of prior trials and reasons for discontinuation or failure when submitting a PA for a step therapy product.
    Step Therapy

    Step therapy / failure requirements

    Multiple products require documentation that the patient had an inadequate response to two preferred alternatives (or one preferred alternative for some agents) before prior authorization will be granted; providers must include trial history and outcomes in the PA.

    • When two‑failure step rules apply, provide dates, medications, doses, and clinical rationale showing inadequate response.
    Step Therapy

    Step therapy example

    CAPLYTA is reserved for FDA‑approved indications and requires trial and failure of at least two formulary alternatives (risperidone, quetiapine, aripiprazole, olanzapine, ziprasidone, lurasidone) unless previously stable on Caplyta or prescribed by/with behavioral health consultation; prior authorization must document these trials or exception.

    • Document trials and failures of the specified formulary alternatives or evidence of prior stability / behavioral health consultation.
    Step Therapy

    Step/sequence requirement

    Common step‑therapy patterns require trying and failing two preferred alternatives before coverage of many non‑preferred products; providers must submit evidence of those trials or documentation of contraindication/allergy.

    • If medical literature evidence is required, include references or clinical data as noted in the product entry.
    Prior Authorization

    Prior authorization for listed drugs

    Several products are reserved pending failure of preferred alternatives or as second‑line options; documentation of trials and failures (often two products) is required for prior authorization.

    • Provide chart notes showing trials, durations, responses, and reasons for discontinuation to support PA requests.
    Documentation Required

    External product-specific PA references

    Some entries require providers to follow external PA documents and submit specified supporting documentation (e.g., specialist notes, lab values, culture/sensitivity results, or medical literature demonstrating superiority); providers must include those items to support approval.

    • Examples: culture/sensitivity and infectious disease consult for Nuzyra; LDL and prior therapy attestation for Nexletol/Nexlizet; HCV genotype/viral load for PEGASYS.
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note

    Definitions and Key Terms

    Step Therapy definition
    DefinitionStep Therapy (ST): A requirement to try specified preferred medicine(s) first; coverage of a step therapy drug requires documentation that the required preferred agent(s) were tried and failed or are medically contraindicated.
    Common applicationOften requires failure of two preferred alternatives before covering a non-preferred product (number may vary by drug).
    ExceptionsExceptions include documented allergy to the generic equivalent or medical contraindication to preferred agents.
    Prior Authorization (PA) definition
    DefinitionPrior Authorization (PA): A requirement to obtain HealthPartners approval for coverage of certain medicines on the drug list before the plan will cover them.
    PurposeEnsures medicines meet plan-specific criteria such as FDA indication, failure of preferred therapies, or documented allergy to generics.
    How usedMany listed products require PA; criteria vary by drug and may reference external product-specific PA documents.
    Reserved for FDA-approved indications definition
    DefinitionReserved for FDA‑approved indications: Coverage limited to uses approved by the FDA unless other criteria or specific exceptions are listed for the product.
    ImplicationOff-label uses are generally not covered unless explicit criteria or external PA documents permit them.
    Typical additional requirementsMay also require prior trials of preferred therapies or documentation of clinical benefit as specified per product.
    Inadequate response to preferred alternatives definition
    DefinitionInadequate response to preferred alternatives: The member has failed therapy with one or more specified preferred formulary agents (commonly two preferred alternatives) or has a medical contraindication to them.
    DocumentationProvider documentation of trial and failure (or contraindication) to preferred agents is required for PA approval.
    VariabilitySome products require failure of one preferred alternative rather than two; check product-specific criteria.
    Reserved for — general definition
    DefinitionReserved for: indicates the product is subject to prior authorization and generally limited to use when the patient has inadequate response to preferred alternatives or has contraindications to them.
    Meaning in listingsUsed as a shorthand in many entries to denote PA reservation; exact conditions (number of failed alternatives, specialist prescribing) depend on the product line.
    Action for providersFollow the product-specific PA criteria or linked external PA document to confirm required documentation.
    Reserved for patients with a documented allergic reaction to the equivalent generic
    DefinitionReserved for patients with a documented allergic reaction to the equivalent generic: Coverage limited to members who have documented allergy to the generic formulation of the product.
    DocumentationPrior authorization must confirm an allergic reaction to the generic equivalent to approve brand coverage.
    Common useFrequently applied to brand products where a generic equivalent exists; absence of allergy documentation may lead to denial.
    Reserved for FDA-approved indications + inadequate response to two preferred alternatives definition
    DefinitionReserved for FDA‑approved indications plus inadequate response to two preferred alternatives: Coverage requires the FDA‑approved indication AND documented inadequate response to two preferred alternatives (or contraindications).
    Provider attestationMay require provider attestation of prior therapies and supporting lab or clinical data as specified (e.g., LDL documentation for lipid agents).
    VariationsSome products specify one preferred alternative rather than two; check the product-specific PA details.
    Reserved for patients with a documented allergic reaction to the equivalent generic (duplicate)
    DefinitionReserved for patients with a documented allergic reaction to the equivalent generic: (duplicate entry) Coverage limited to members with confirmed allergy to the generic; PA required to verify allergy.
    Reason for duplicationThis phrasing is used repeatedly across the drug list for many brand/generic pairs.
    Denial riskRequests lacking documentation of an allergic reaction to the generic may be denied.
    Reserved for FDA-approved indications (duplicate)
    DefinitionReserved for FDA‑approved indications: (duplicate) Coverage limited to FDA‑approved uses unless other criteria or exceptions are specified.
    Typical additional rulesMay require prior failure of preferred alternatives or specific documentation per product.
    Provider actionConsult the product entry or linked PA document for exact criteria.
    IR Opioids definition (supply limits)
    DefinitionIR Opioids (new-user supply limits): Immediate‑release opioid formulations for new users are limited to a 7‑day supply for the first fill and a total 14‑day supply per episode; longer therapy requires prior authorization with provider attestation.
    Tramadol ER linkageTramadol ER requires prior authorization after a minimum 30 days continuous use of tramadol IR (provider attestation that opioid management follows guidelines).
    Provider attestationPA for longer opioid therapy requires attestation that therapy is managed per standard opioid prescribing guidelines, including assessment of risk factors.
    CF treatment center management definition
    DefinitionCF treatment center management: Certain inhaled Tobramycin formulations must be prescribed and managed by specialists from a cystic fibrosis treatment center to qualify for coverage.
    Quantity and renewalTobramycin ampules/PAK: quantity limited to one 56‑count carton per 56 days; initial approvals 12 months; renewals annually with CF center visit documentation and demonstration of effectiveness.
    Denial riskPA may be denied if Tobramycin is not prescribed/managed by a CF treatment center or required documentation is missing.

    Initial Therapy Requirements and Durations

    Ophthalmic initial approvals

    When specified

    CYSTADROPS/CYSTARAN initial approval: Initial approvals will be provided for three months for cystinosis ophthalmic products.3 months

    Explicit initial approval duration.

    Pulmozyme initial therapy

    Pulmozyme initial approval

    Pulmozyme initial: Reserved for cystic fibrosis patients prescribed and managed by specialists from a cystic fibrosis treatment center. Initial approvals provided for 12 months.12 months

    Specialist management required.

    Initial therapy rules

    Initial approval durations specified for some products

    Somatuline/Somatostatin analogues initial: Initial approvals are for six months for patients meeting criteria (e.g., Somatuline Depot, Somavert); reauthorizations provided annually for responders with documented effect.6 months

    Applies to somatostatin analogues.

    Initial therapy requirements

    Initial approval conditions (general across products):

    Brand reserved for allergy to generic: Initial coverage reserved when patient has documented allergic reaction to equivalent generic.

    Common reservation reason.

    Failure of preferred alternatives: Initial coverage reserved when patient has inadequate response to preferred dosage form(s) or two preferred alternatives, or has documented medical contraindication to preferred products.

    Documentation of prior trials typically required.

    Continuation and Renewal Criteria

    Dalfampridine continuation

    Continuation criteria when specified

    Dalfampridine continuation: Patients meeting initial criteria who have documented improvement in ambulation after six months will be approved for one year; annual approvals thereafter require continued positive response.improvement in ambulation

    Renewal timeline defined.

    Cystinosis ophthalmic renewals

    Ophthalmic cystinosis product renewals

    CYSTADROPS/CYSTARAN renewal: Renewals require documentation of clinical treatment effect (slit lamp exam notes) and may be approved up to one year following initial 3‑month approval.slit lamp exam documentation

    Initial 3‑month approval then renewals up to 1 year.

    Pulmozyme continuation

    Renewal condition for Pulmozyme

    Pulmozyme renewal: Annual renewal requires documentation that the patient was seen within the last 12 months at a cystic fibrosis treatment center AND that the medication is effective.seen within 12 months

    Initial approval 12 months.

    Continuation example

    Example continuation rule present in extract:

    Re-authorization for Reyvow: Initial authorization will be provided for 6 months. Re-authorization will be provided for 12 months.initial 6 months; reauthorization 12 months

    Illustrative example of duration-based continuation.

    Continuation therapy

    Renewal terms where specified

    Somatuline/Somavert renewal: Initial approvals for six months; annual approvals thereafter for responders with demonstrated effect.6 months initial

    Specialty agent continuation pattern.

    Tobramycin renewal

    Renewal requirements for Tobramycin inhalation products:

    Tobramycin renewal: Renewals provided annually with documentation that the patient has been seen within the last 12 months at the cystic fibrosis treatment center AND that the medication is effective.annual renewal with CF center visit documentation

    Initial approvals 12 months; quantity limits apply.

    Step Therapy Rules and Required Trials

    RequirementNotes / Examples
    Try and fail preferred therapies before covering non-preferred or specialty agents
    Exceptions include documented allergy to the equivalent generic or medical contraindication to preferred alternatives
    RequirementDocumentation expected
    Document prior trials of specified preferred alternatives before approval
    Medical chart notes or prior therapy history showing inadequate response or intolerance to the preferred agent(s); literature support when superiority over preferred alternatives is claimed
    StepExample
    Step 1: Confirm FDA‑approved indication and behavioral health consultation when required
    Example: CAPLYTA requires trial and failure of at least two formulary alternatives (risperidone, quetiapine, aripiprazole, olanzapine, ziprasidone, lurasidone) unless patient is previously stable or managed with behavioral health consultation
    RequirementProduct-specific note
    Require trial and inadequate response to specified alternatives (often two) prior to approval
    Example: BRIVIACT reserved for patients with inadequate response to two or more preferred seizure medications (one must be levetiracetam)
    RequirementThreshold / Count
    Prior trials of a specified number of preferred formulary agents must be completed before approving a non-preferred product
    Examples: some drugs require two preferred alternatives; DEXLANSOPRAZOLE DR may require failure of three preferred alternatives
    RequirementDocumentation / Exceptions
    Documented trials and failures of preferred agents as specified per product
    Some products accept documented contraindication or prior stability on the requested medication as exceptions
    RequirementCoverage rule
    Must have tried and failed two preferred alternatives (unless contraindicated)
    Applies across many long-acting opioid and non-opioid products; documentation of prior failures or medical contraindication required
    RequirementProvider attestation detail
    Provider attestation that opioid therapy is managed per standard opioid prescribing guidelines
    Attestation must confirm management per guidelines and prior trial/failure where required (see long-acting opioid rules)
    RequirementMinimum prior trial
    Provider attestation for long-acting opioids that a prior adequate trial of a short-acting opioid occurred
    Minimum prior trial duration: 30 days of continuous use of a short-acting opioid prior to long-acting opioid approval
    RequirementScope
    Trials of preferred alternatives are required before prior authorization approval for many products
    Applies to diverse drug classes; number of required prior alternatives varies by product (commonly one or two)
    RequirementCommon rule
    Trial and failure of preferred alternatives required prior to coverage for many products
    Documentation of inadequate response to one or two preferred alternatives (varies by product) or medical contraindication is expected
    RequirementAdditional provider requirement
    Provider attestation that therapy is managed per opioid prescribing guidelines
    For long-acting opioids, attestation must state prior short-acting opioid trial of minimum 30 days continuous use
    RequirementCoverage implication
    Trial and failure of preferred alternatives before coverage of the listed product
    Where required, approval depends on documentation that preferred alternatives were tried and ineffective or not tolerated
    RequirementException
    Trial and failure of preferred alternatives OR documented medical contraindication to preferred agents
    Some products accept medical contraindication in lieu of trials; specific products may require additional documentation
    When prior authorization is requiredProvider action
    Prior authorization is required when step therapy failure criteria are met or when there is documented allergy/intolerance to preferred/generic alternatives
    Providers must submit documentation of prior trials, contraindications, or documented allergy to the preferred/generic alternative to support authorization
    RequirementAdditional conditions
    Failure of preferred alternatives or documented contraindication required; some products require specialist prescribing or specific monitoring
    Examples: certain specialty agents require prescribing by a specialist and documentation of monitoring or specialist visit for renewals
    RequirementCoverage note
    Must have tried preferred alternatives unless there is a documented contraindication or allergy
    Where allergy to generic is documented, brand may be reserved for that patient with PA documentation
    RequirementAcceptable documentation
    Documented trial and failure of preferred products OR documented contraindication to preferred products required prior to approval
    Acceptable supporting documentation includes chart notes, prior medication history, and provider attestation; some products require literature evidence or external PA forms

    Key Clinical Thresholds and Quantity/Code Notes

    Opioid trial duration — minimum of 30 days of continuous use
    Minimum durationMinimum of 30 days of continuous use of a short‑acting opioid is required as an adequate trial before PA for long‑acting opioids.
    ContextThis trial duration is the standard used when provider attestation for long‑acting opioid therapy is required.
    Related requirementProvider attestation that therapy is managed per standard opioid prescribing guidelines must accompany PA requests for long‑acting opioids.
    Gattex parenteral nutrition dependence — >= 1 year and at least 3 days per week
    DefinitionGattex requirement: Dependence on parenteral nutrition for at least 1 year and at least 3 days per week is required for Gattex (teduglutide) PA.
    Approval durationInitial approvals granted for three months; reauthorizations provided for up to one year with documented reduction in parenteral nutrition volume.
    Clinical contextApplies to adult patients with short bowel syndrome significantly impaired by chronic parenteral nutrition requirements (e.g., >=4 L daily).
    LDL cholesterol threshold — >= 70 mg/dL
    ThresholdLDL cholesterol >= 70 mg/dL is required to meet inadequate response criteria for certain lipid‑lowering agents (e.g., Nexletol/Nexlizet).
    Required prior therapyMember must have had high‑intensity statin therapy (or documented contraindication) and an inadequate response to ezetimibe unless contraindicated or allergic.
    Authorization durationApprovals are given for one year; reauthorizations require provider attestation of LDL reduction.
    Short-acting opioid trial duration — minimum of 30 days of continuous use
    Minimum durationMinimum of 30 days of continuous use of a short‑acting (immediate‑release) opioid is required before considering prior authorization for long‑acting or ER opioids.
    ApplicationThis requirement supports provider attestation that the patient had an adequate recent trial of short‑acting opioids prior to long‑acting therapy.
    Related policyApplies across long‑acting opioid entries (fentanyl patches, morphine ER, hydrocodone ER, etc.).
    Documented testosterone deficiency threshold — < 300 ng/dL
    ThresholdDocumented testosterone deficiency: serum testosterone < 300 ng/dL required when used for FDA‑approved indications for certain testosterone products.
    Alternate pathwayOr, documentation of a diagnosis of gender dysphoria may satisfy eligibility for some formulations.
    Additional requirementsSome testosterone products also require inadequate response or contraindications to two or more preferred alternatives.
    Tascenso ODT age/weight criteria — age >=10 years and weight <=40 kg
    CriteriaTascenso ODT eligibility: Patient must meet all three — age 10 years or older, weight <= 40 kg, and inability to take oral Gilenya capsules.
    ApplicationThis is product‑specific and must be documented for PA approval of Tascenso ODT 0.25 mg tablet.
    SourceSpecified in the TASCENSO ODT product entry in the PA list.
    Testosterone deficiency threshold (duplicate) — < 300 ng/dL
    ThresholdDocumented testosterone deficiency threshold (duplicate): serum testosterone < 300 ng/dL required for FDA‑approved indications in select testosterone products.
    Alternate eligibilityDiagnosis of gender dysphoria may be an alternative pathway for coverage for some testosterone formulations.
    DocumentationPA requires lab documentation of testosterone level when used to demonstrate deficiency.
    Tramadol ER prior IR trial duration — minimum of 30 days continuous use
    RequirementTramadol ER prior authorization requires a prior adequate trial of tramadol immediate‑release for a minimum of 30 days continuous use.
    Age limitsTramadol is reserved for adults and children 12 years of age and older; unique age edits apply.
    Related editsIR opioid new‑user supply limits apply (7‑day first fill, 14‑day episode); longer therapy requires PA with provider attestation of opioid management.

    Product Quantity Limits and Dispensing Rules

    CAYSTON quantity limit — one 28-day package
    LimitCAYSTON quantity limit: one 28‑day package per month.
    Site of careCAYSTON must be prescribed and managed by specialists from a cystic fibrosis treatment center; initial approval 12 months with annual renewals requiring documentation and effectiveness.
    Renewal requirementRenewals require evidence of specialist visit within the prior 12 months and that medication is effective.
    TOBRAMYCIN 300 MG/4 ML AMPULE, 300 MG/5 ML AMPULE, PAK — one 56-count carton
    LimitTOBRAMYCIN 300 MG/4 ML AMPULE, 300 MG/5 ML AMPULE, PAK — quantity limit: one 56‑count carton per 56 days.
    Indication and managementReserved for cystic fibrosis patients with Pseudomonas aeruginosa and must be prescribed/managed by specialists from a CF treatment center.
    Approval and renewalInitial approvals provided for 12 months; renewals annually with documentation of CF center visit within last 12 months and medication effectiveness.

    Site-of-Care and Specialty Management Requirements

    Note
    Note

    Background and Policy Scope

    Step therapy is a utilization management approach that requires trying one or more preferred medicines first; a prior authorization or exception is needed when preferred agents have not been tried, and documentation of trials, failures, or contraindications must be submitted to support coverage of non‑preferred drugs.